Since hitting multi-year highs back in March, it has been a steady decline for ASX gold stock Regis Resources Ltd (ASX: RRL). 

It is an established multi-mine gold producer and one of the largest ASX-listed gold producers with an all-Australian asset base. 

The Duketon Gold Project (located in the Laverton region of WA) is RRL’s flagship project. 

Rollercoaster for gold stocks 

Like many other ASX gold stocks, it enjoyed a surge into early 2026 as the gold price climbed to record highs. 

This was driven by strong safe-haven demand, expectations of lower interest rates in major economies, central bank buying, and investor optimism that miners’ profits and cash flows would increase. 

However, like much of the sector, Regis Resources shares have since fallen as gold prices retreated from their peaks, and investors rotated into riskier assets amid improving market sentiment. 

Since peaking at over $9.40 per share in March, it has now fallen over 40% and is now sitting at around $5.65 per share. 

However, this ASX gold stock is now generating broker interest. 

Yesterday, the team at Bell Potter updated their outlook on Regis Resources, which included a retained buy recommendation and strong upside. 

Here’s what the broker had to say. 

FY27 guidance lifted

Late last week, Regis Resources released an updated FY27 outlook. 

As Laura Steward reported, the company lifted its FY27 production guidance, aiming for 360,000–400,000 ounces of gold at a group all-in sustaining cost of $2,990–$3,390 per ounce.

Bell Potter said this production is similar to FY26. 

Higher production at Duketon should offset slightly lower production at Tropicana. 

Costs are expected to rise because the company is mining more expensive ounces and facing higher diesel costs. 

Ramelius is also increasing spending on mine development and exploration, which should support future growth but will lift capital spending in FY27.

Healthy upside for ASX gold stock

Based on this guidance, Bell Potter retained its buy recommendation on this ASX gold stock. 

However the broker has lowered its price target to $8.45 (previously $9.45). 

However, from yesterday’s closing price, this still indicates an upside of almost 50%. 

Overall, we remain positive towards RRL’s all-Australian, multi-mine asset portfolio, leverage to the gold price and its fully unhedged, debt free position. However, higher costs and CAPEX cut our NPV-based valuation 11%, to $8.45/sh. We retain our Buy recommendation.

Bell Potter isn’t the only expert tipping a rebound for gold stocks.

Recently, the VanEck published a report suggesting many ASX gold shares remain attractively valued after the recent pullback.

The post Broker jumps on board this quality ASX gold stock and tips 50% upside appeared first on The Motley Fool Australia.

More reading

• Which ASX gold stock has Macquarie tipped to jump more than 20%?
• 5 things to watch on the ASX 200 on Tuesday
• Regis Resources upgrades FY27 production guidance and cost outlook
• Buy, hold, sell: Regis Resources, Mineral Resources, Woolworths shares
• Regis Resources steps back from Vault Minerals bid, secures break fee

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

These three ASX healthcare stocks have staged a remarkable comeback in recent weeks.

The latest recovery follows a brutal 12 months for the sector.

The S&P/ASX 200 Health Care Index (ASX: XHJ) fell 39% over the year to a nine-year low on 3 June 2026. Since then, the sector has bounced roughly 20% in a single month.

The broader S&P/ASX 200 Index (ASX: XJO) has risen just 0.1% over the same period.

So which stocks deserve a spot on your watchlist right now?

Let’s take a look at three.

Why ASX healthcare stocks are rebounding

Healthcare was the worst-performing sector on the ASX in FY26.

Why? A stronger Australian dollar, higher costs, and regulatory uncertainty all weighed on returns.

When a sector falls that far that fast, bargain hunters tend to circle, and that is exactly what has been happening since early June.

Institutional investors have rotated out of resources and into beaten-down healthcare names.

Here are three ASX healthcare stocks riding that recovery.

Pro Medicus

Pro Medicus Ltd (ASX: PME) is one of the highest-quality software businesses on the ASX.

The company’s Visage platform helps hospitals view, manage, and share medical images.

Over the last year, PME shares have been on a wild ride.

Shares sank to a 52-week low of $107.75 on 24 February before rebounding sharply. In good news for the company, the recovery has largely been fuelled by a run of new contract wins and renewals.

Brokers remain optimistic, too.

According to Morgans, the broker has reaffirmed an accumulate rating and $230.00 price target on Pro Medicus shares. Citi is even more upbeat, with a buy rating and a $240 target.

Telix Pharmaceuticals

Telix Pharmaceuticals Ltd (ASX: TLX) is the ASX’s flagship radiopharmaceutical company.

The company develops targeted radiation products to image and treat cancer.

Unfortunately, the stock has been volatile over the past year, but there is plenty happening beneath the surface.

Telix has struck a strategic radiopharma collaboration with US biotech Regeneron under which the two companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies on a 50/50 cost-and-profit-sharing basis. Under this deal, Telix will gain access to Regeneron’s antibody platform. Telix will also be able to expand its reach in solid-tumour radiopharma without bearing the full development burden itself

The company also has several FDA catalysts in 2026, led by the resubmitted NDA for TLX101-Px, branded Pixclara, an investigational PET imaging agent for glioma that the FDA accepted in April.

Perhaps as a result, management has guided to FY26 revenue of US$950 million to US$970 million.

For investors comfortable with greater levels of risk, Telix is an intriguing option among ASX healthcare stocks.

CSL

CSL Ltd (ASX: CSL) is the giant of these three ASX healthcare stocks.

The blood products and vaccines business lost around half its value over the past year, a de-rating that has wiped out years of gains.

However, the tide may be turning.

CSL shares have surged about 35% since their early-June low to $122.89.

Broker views remain split.

Morgans has a buy rating and $147.59 price target on CSL shares, whilst the consensus target sits near $140.15, implying roughly 14% upside.

The key test for CSL shares comes with the FY26 result on 19 August.

Foolish takeaway for ASX healthcare stocks

These three ASX healthcare stocks each tell a different story.

Pro Medicus offers quality and momentum. Telix offers pipeline optionality. CSL offers a potential turnaround at a beaten-down price.

All three carry risk, and recoveries can stall.

But for investors hunting the next leg of the rebound, these ASX healthcare stocks are well worth watching.

The post Top 3 ASX healthcare stocks to watch appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals: Q2 2026 revenue jumps 21%
• CSL vs Telstra shares, which should I buy?
• I’d listen to Warren Buffett and buy cheap ASX shares
• Buy, hold, sell: Weebit Nano, Metals X, Pro Medicus shares
• Down 50%+: Are these ASX healthcare shares finally worth buying?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended CSL, Pro Medicus, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Andean Silver Ltd (ASX: ASL) share price is in focus today after the company pinpointed a bonanza-grade silver-gold trend at its Cerro Bayo Project’s Juanita prospect, returning surface samples up to 62,663 grams per tonne silver equivalent.

What did Andean Silver report?

• Surface sampling at Juanita prospect returned assays up to 62,663g/t silver equivalent (25,047g/t Ag & 453.2g/t Au), or 755g/t gold equivalent
• High-grade breccia zone defined over 2 kilometres strike length, with observed widths up to 18 metres
• Historic drilling and channel results include 17.1m @ 194g/t AgEq and 1.6m @ 1,209g/t AgEq
• Juanita sits outside the existing Cerro Bayo 136Moz AgEq mineral resource
• Andean Silver held $53.4 million in cash at the end of March quarter 2026

What else do investors need to know?

The Juanita discovery marks the third major greenfield exploration area identified by Andean Silver at Cerro Bayo, indicating a pathway for further growth beyond current resources. Juanita’s mineralisation differs from the typical epithermal veins of the district, displaying high-grade precious metals across multiple events and a large breccia system.

Recent mapping suggests past drilling was limited, with much of Juanita’s most prospective zones remaining untested. The company is now embarking on detailed geological work and systematic sampling along the 2-kilometre trend to firm up priority drill targets.

What did Andean Silver management say?

Andean Silver Managing Director Matthew Allen said:

Juanita is emerging as a potentially significant silver-gold prospect. Its mineralisation differs from the vein-style deposits common across the Company’s tenure, with high-grade silver and gold occurring over a substantial strike length and through multiple mineralising events.

Juanita historically has remained underexplored for 20 years due to the subtle surface expression of the system exposed on surface and limited intersection in historic scout drilling.

Juanita represents a third new large exploration area identified outside the existing resources at the Cerro Bayo Project, which include the Guanaco and Droughtmaster corridors, building Andean’s future prospect pipeline.

What’s next for Andean Silver?

Andean Silver plans to accelerate mapping, channel sampling, and drill planning at Juanita, targeting high-grade zones for maiden drill tests. Broader objectives include ramping up both brownfields and greenfields exploration throughout Cerro Bayo to grow resources and restart production.

The company is well funded to support these campaigns, with feasibility and resource upgrade studies running in parallel. Andean aims to transition Cerro Bayo from an exploration project into a near-term development and production asset by late 2027.

Andean Silver share price snapshot

Over the past 12 months, Andean Silver shares have risen 31%, outperforming the S&P/ASX All Ords Index (ASX: XAO), which has risen 1% over the same period.

View Original Announcement

The post Andean Silver Bonanza silver-gold unearthed at Cerro Bayo’s Juanita prospect appeared first on The Motley Fool Australia.

More reading

• Ophir High Conviction Fund announces FY26 unfranked distribution
• 5 ASX All Ords shares that ripped 200% to 400% in FY26